RxDoctor Payments Data

Lane Spero, MD

Orthopaedic Surgery of the Spine · Torrington, CTNPI 1235197328

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Stryker at 51.0% of the total. Reporting peaked in 2023 at $21,346 and has fallen 83.7% since, to $3,484 in 2025.

$67,619in general payments, 2019–2025

Across 301 payments — averaging $224.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$34K
  • Clariance, Inc.$15K
  • Alphatec Spine, Inc$6K
  • Royal Biologics, Inc.$5K
  • Smith+Nephew$2K
  • Highridge Medical LLC$1K
  • plus $5K from 31 others

What the payments were for

  • Royalty or licence$910%
  • Consulting fees$33,89750%
  • Travel & lodging$16,12024%
  • Food & beverage$17,51126%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,619 in reported general payments places this provider in the 70th percentile of 25 orthopaedic surgery of the spine providers in Connecticut.

See all orthopaedic surgery of the spine providers in Connecticut

Medicare billing

Part B allowed, 2024
$63,293
Medicare patients
111
Services billed
466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin22$366
Methylprednisolone53$348
Tramadol Hcl17$82
Meloxicam42$75

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery of the spine in Torrington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →